EXACT Sciences Co. (NASDAQ:EXAS) Insider Sells $6,494,260.96 in Stock

EXACT Sciences Co. (NASDAQ:EXAS) insider Kevin T. Conroy sold 123,512 shares of the business’s stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $52.58, for a total value of $6,494,260.96. Following the transaction, the insider now owns 953,564 shares of the company’s stock, valued at approximately $50,138,395.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

EXACT Sciences Co. (EXAS) opened at $52.62 on Friday. The stock has a market capitalization of $6,300.00, a price-to-earnings ratio of -45.76 and a beta of 0.68. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01. EXACT Sciences Co. has a 12-month low of $16.95 and a 12-month high of $63.60.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07. The business had revenue of $72.60 million for the quarter, compared to the consensus estimate of $65.03 million. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The business’s quarterly revenue was up 158.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.36) earnings per share. equities research analysts anticipate that EXACT Sciences Co. will post -1.1 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Krilogy Financial LLC increased its position in shares of EXACT Sciences by 1,460.0% in the 2nd quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock valued at $138,000 after acquiring an additional 3,650 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in shares of EXACT Sciences by 17.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 600 shares during the period. Crow Point Partners LLC acquired a new position in shares of EXACT Sciences in the 4th quarter valued at $145,000. Oppenheimer Asset Management Inc. increased its position in shares of EXACT Sciences by 2,925.7% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock valued at $150,000 after acquiring an additional 3,072 shares during the period. Finally, Johnson Financial Group Inc. increased its position in shares of EXACT Sciences by 25.9% in the 2nd quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 1,000 shares during the period. 82.39% of the stock is currently owned by hedge funds and other institutional investors.

EXAS has been the subject of a number of research reports. Leerink Swann reiterated an “outperform” rating and issued a $50.00 price target (up previously from $45.00) on shares of EXACT Sciences in a report on Thursday, September 21st. Zacks Investment Research upgraded EXACT Sciences from a “hold” rating to a “buy” rating and set a $51.00 price target for the company in a report on Tuesday, September 26th. Canaccord Genuity reiterated a “buy” rating and issued a $60.00 price target (up previously from $45.00) on shares of EXACT Sciences in a report on Tuesday, October 3rd. Robert W. Baird reiterated a “buy” rating and issued a $49.00 price target on shares of EXACT Sciences in a report on Friday, October 6th. Finally, Bank of America set a $56.00 price objective on shares of EXACT Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. Eight equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $50.58.

WARNING: This story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2018/01/13/exact-sciences-co-exas-insider-sells-6494260-96-in-stock.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply